GLP-1

News

Novo Nordisk has said a real-world survey of Wegovy shows it can reduce 'food noise', persistent, intrusive, or repetitive thoughts about eating.

News

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.

News

Ametris launches a collaboration with pharma companies that aims to show how digital endpoints can be used in obesity trials.

News

Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy works better than Eli Lilly's fast-growing rival Zepbound.